Letermovir for CMV Prevention After Lung Transplantation
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is an interventional, open-label, single center, pilot study with historical controls to
test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in
adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).